News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
GlaxoSmithKline, Human Genome Sciences, Inc. Get Fast Review For Lupus Drug
August 19, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Aug 19 (Reuters) - A keenly awaited new lupus drug from GlaxoSmithKline Plc (GSK.L) and Human Genome Sciences Inc (HGSI.O) will get a priority review from U.S. regulators, potentially clearing the way for its approval by mid-December.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Rare disease
Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership
February 17, 2026
·
3 min read
·
Annalee Armstrong
CDC
CDC Left Leaderless Again After Acting Director Departs HHS
February 16, 2026
·
1 min read
·
Tristan Manalac
Complete response letters
FDA Rejects Disc’s Rare Blood Disease Drug Amid Reports of Prasad’s Skepticism
February 16, 2026
·
3 min read
·
Tristan Manalac
Government
‘Just Agree to It:’ Pazdur Said He Was Told To Cosign FDA’s Reduced Trial Requirements
February 16, 2026
·
2 min read
·
Tristan Manalac
